Literature DB >> 30185357

Safety of retrievable inferior vena cava filters in patients with the antiphospholipid syndrome.

Sara Baig1, Joseph Bert2,3, Elie Gertner2,3.   

Abstract

OBJECTIVE: Consideration for placement of an inferior cava filter arises in patients with APS where cessation of anticoagulation is necessary or thrombotic complications continue despite maximal anticoagulation. Permanent IVC filters are recommended to be avoided. We evaluated the safety of placement and removal of retrievable inferior vena cava filters in patients with APS.
METHODS: Case series of 5 patients with APS and aPL antibodies who had placement and removal of retrievable IVC filter (because of contraindication to anticoagulation or ongoing thrombosis despite full anticoagulation) to assess for safety, presence of clots in the vena cava or on the filter while in the body, evidence of PE, or clot on the explanted filter.
RESULTS: Insertion and removal, even while on anticoagulation, was safe. There was no evidence of clot in the vena cava, on the filter or pulmonary embolism in all cases.
CONCLUSION: Where necessary, retrievable IVC filters may be safer in APS patients but should not be left in for long periods of time.

Entities:  

Year:  2018        PMID: 30185357      PMCID: PMC6072695          DOI: 10.5152/eurjrheum.2018.17091

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  14 in total

Review 1.  Systematic review of the use of retrievable inferior vena cava filters.

Authors:  Luis F Angel; Victor Tapson; Richard E Galgon; Marcos I Restrepo; John Kaufman
Journal:  J Vasc Interv Radiol       Date:  2011-11       Impact factor: 3.464

2.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

Review 3.  The pathogenesis of the antiphospholipid syndrome.

Authors:  Bill Giannakopoulos; Steven A Krilis
Journal:  N Engl J Med       Date:  2013-03-14       Impact factor: 91.245

4.  Temporary Inferior Vena Cava Filters: How Do We Move Forward?

Authors:  Edward J Arous; Louis M Messina
Journal:  Chest       Date:  2016-03-21       Impact factor: 9.410

Review 5.  A Critical Review of Available Retrievable Inferior Vena Cava Filters and Future Directions.

Authors:  Jennifer P Montgomery; John A Kaufman
Journal:  Semin Intervent Radiol       Date:  2016-06       Impact factor: 1.513

6.  Recurrent pulmonary embolism despite inferior vena cava filter placement in patients with the antiphospholipid syndrome.

Authors:  Joseph Cherian; Elie Gertner
Journal:  J Clin Rheumatol       Date:  2005-02       Impact factor: 3.517

7.  Lethal pulmonary embolism in a patient with primary antiphospholipid syndrome and a vena caval filter.

Authors:  H C Lee; M B Laya
Journal:  Chest       Date:  1994-01       Impact factor: 9.410

8.  Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry".

Authors:  Ricard Cervera; Silvia Bucciarelli; Miguel A Plasín; José A Gómez-Puerta; Joan Plaza; Guillermo Pons-Estel; Yehuda Shoenfeld; Miguel Ingelmo; Gerard Espinos
Journal:  J Autoimmun       Date:  2009-03-26       Impact factor: 7.094

9.  Insertion of inferior vena cava filters in patients with the antiphospholipid syndrome.

Authors:  Eyal Zifman; Pnina Rotman-Pikielny; Tatiana Berlin; Yair Levy
Journal:  Semin Arthritis Rheum       Date:  2008-04-18       Impact factor: 5.532

10.  The Development of Marked Collateral Circulation due to Inferior Vena Cava Filter Occlusion in a Patient with Chronic Thromboembolic Pulmonary Hypertension Complicated with Anti-phospholipid Syndrome.

Authors:  Hajime Kasai; Nobuhiro Tanabe; Ken Koshikawa; Yasutaka Hirasawa; Toshihiko Sugiura; Seiichiro Sakao; Koichiro Tatsumi
Journal:  Intern Med       Date:  2017-04-15       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.